UNIVERSITY OF IOWA HOSP & CLINICS
- Type
- Teaching hospital
- Where
- IOWA CITY, IA
- Medicare CCN
- 160058
- Received
- $20,538,114 in 2,240 records, 2021 ($830,848 general, $19,707,266 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2021 | General payment | 262 | $830,848 |
| 2021 | Research payment | 1,978 | $19,707,266 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,978 | $19,707,266 |
| Royalty or License | 3 | $254,419 |
| Grant | 25 | $195,315 |
| Space rental or facility fees (teaching hospital only) | 164 | $152,317 |
| Long term medical supply or device loan | 14 | $140,048 |
| Consulting Fee | 10 | $67,775 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 31 | $12,019 |
| Education | 8 | $7,692 |
| Charitable Contribution | 6 | $1,256 |
| Gift | 1 | $5 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | Merck Sharp & Dohme LLC | $201,974 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $145,256 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $136,810 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $124,087 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $118,576 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $117,281 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $91,475 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $65,148 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab versus Placebo as Adjuvant The | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $58,625 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $53,569 | Research payment | In-kind items and services | Drug, ONCOLOGY | A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olap | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $48,724 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase 1b,2 study of immune and targeted combination therapies in participants with RCC | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $48,724 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase 1b,2 study of immune and targeted combination therapies in participants with RCC | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $43,369 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $43,273 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N | 2021 |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $40,250 | Research payment | Cash or cash equivalent | Artis Q floor Device, AT - Fixed interventional x-ray/angiography fluoroscopy | Iowa Ortega Neuro Clinical AT | 2021 |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $40,250 | Research payment | Cash or cash equivalent | Artis Q floor Device, AT - Fixed interventional x-ray/angiography fluoroscopy | Iowa Ortega Neuro Clinical AT | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $28,102 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus N | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $27,112 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With | 2021 |
| 2021-12-31 | Monteris Medical Corporation | $25,000 | Long term medical supply or device loan | Cash or cash equivalent | Neuroblate Device, Neuroblate | 2021 | |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $22,870 | Research payment | Cash or cash equivalent | Somatom Force Device, CT and RO incl. Computed Tomography and Radiation Oncology | Functional Lung Imaging with Dualenergy CT | 2021 |
| 2021-12-31 | Intuitive Surgical, Inc. | $21,050 | Long term medical supply or device loan | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $17,546 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $15,152 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $13,778 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $13,055 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Study of Pembrolizumab MK-3475 as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma KEYNOTE-224 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $10,032 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $10,013 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $9,466 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $9,206 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab versus Placebo as Adjuvant The | 2021 |
| 2021-12-31 | UCB SA | $8,729 | Research payment | Cash or cash equivalent | The Healey Platform trial | 2021 | |
| 2021-12-31 | UCB SA | $8,729 | Research payment | Cash or cash equivalent | The Healy Platform Trial | 2021 | |
| 2021-12-31 | KARL STORZ Endoscopy-America | $7,319 | Research payment | In-kind items and services | Blue Light Flexible Cystoscopy with Cysview Study | 2021 | |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $6,761 | Research payment | In-kind items and services | FASENRA Biological, Respiratory | A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate th | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $6,599 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $4,450 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, P | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $4,359 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $3,557 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Co | 2021 |
| 2021-12-31 | Intuitive Surgical, Inc. | $3,400 | Long term medical supply or device loan | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | Intuitive Surgical, Inc. | $3,152 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2021 | |
| 2021-12-31 | Siemens Medical Solutions USA, Inc. | $2,250 | Research payment | Cash or cash equivalent | UIowa2020MRIPR1414Ashwath | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $2,200 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monot | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $2,171 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2 Study of Pembrolizumab MK-3475 as Monotherapy in Subjects with Advanced Hepatocellular Carcinoma KEYNOTE-224 | 2021 |
| 2021-12-31 | Merck Sharp & Dohme LLC | $1,290 | Research payment | In-kind items and services | Drug, INFECTIOUS DISEASE | A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and,or Viral Resistance Patterns of Subject | 2021 |
| 2021-12-31 | ABBVIE INC. | $1,116 | Research payment | In-kind items and services | A Phase I Study of ABBV-011 as a Single-Agent and in Combination with Budigalimab (ABBV-181) in Subjects with Relapsed o | 2021 | |
| 2021-12-31 | AstraZeneca UK Limited | $1,030 | Research payment | In-kind items and services | BYDUREON Drug, Cardiovascular and Metabolism | A Phase 3 Double Blind Placebo Controlled Randomized Multi Center Study To Assess the Safety and Efficacy of Exenatide O | 2021 |
| 2021-12-31 | AstraZeneca Pharmaceuticals LP | $932 | Research payment | In-kind items and services | FARXIGA Drug, Cardiovascular and Metabolism | A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic | 2021 |
| 2021-12-31 | ABBVIE INC. | $611 | Research payment | In-kind items and services | A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (A | 2021 | |
| 2021-12-31 | Merck Sharp & Dohme LLC | $483 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2021 |
| 2021-12-31 | Janssen Research & Development, LLC | $131 | Research payment | Cash or cash equivalent | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2021 | |
| 2021-12-30 | Merit Medical Systems Inc | $3,045 | Research payment | Cash or cash equivalent | Wrapsody Endovascular Stent Graft System Device, Radiology | The Merit Wrapsody AV Access Efficacy Study | 2021 |
| 2021-12-30 | Bio-Rad Laboratories, Inc. | $1,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Liquichek Device, Controls | 2021 | |
| 2021-12-30 | ABBVIE INC. | $834 | Research payment | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | A Phase 4 Study to Compare US Marketed Creon Drug Product with Drug Product Manufactured with a Modernized Process at an | 2021 |
| 2021-12-30 | ABBVIE INC. | $660 | Research payment | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | A Phase 4 Study to Compare US Marketed Creon Drug Product with Drug Product Manufactured with a Modernized Process at an | 2021 |
| 2021-12-29 | Genentech, Inc. | $10,250 | Research payment | Cash or cash equivalent | Xolair Biological, Immunology | USING OBJECTIVE PATIENT CENTRIC MEASURES TO SHOW IMPACT OF OMALIZUMAB ON ASTHMA IMPROVEMENT | 2021 |
| 2021-12-28 | ABBVIE INC. | $23,355 | Research payment | Cash or cash equivalent | A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (A | 2021 | |
| 2021-12-28 | PFIZER INC. | $8,314 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-12-28 | PROGENICS PHARMACEUTICALS, INC. | $4,600 | Research payment | Cash or cash equivalent | PYLARIFY Drug, RADIOPHARMACEUTICAL | Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant | 2021 |
| 2021-12-27 | Janssen Research & Development, LLC | $4,777 | Research payment | Cash or cash equivalent | Prospective Multi Center double blind randomized active controlled triple dummy parallel group sequential adaptive Phase | 2021 | |
| 2021-12-25 | PFIZER INC. | $10,835 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-12-24 | PFIZER INC. | $8,767 | Research payment | Cash or cash equivalent | A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PH | 2021 | |
| 2021-12-23 | Merck Sharp & Dohme LLC | $48,234 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph | 2021 |
| 2021-12-23 | Merck Sharp & Dohme LLC | $28,067 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection | 2021 |
| 2021-12-23 | PFIZER INC. | $21,821 | Research payment | Cash or cash equivalent | MAGNETISMM3 AN OPENLABEL MULTICENTER NONRANDOMIZED PHASE 2 STUDY OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS W | 2021 | |
| 2021-12-23 | PFIZER INC. | $10,971 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-12-23 | PFIZER INC. | $1,395 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EF | 2021 | |
| 2021-12-23 | PFIZER INC. | $549 | Research payment | Cash or cash equivalent | AN OPENLABEL STUDY IN ADOLESCENT AND ADULT SEVERE COAGULATION FACTOR ACTIVITY 1 HEMOPHILIA A OR B PATIENTS WITH OR WITHO | 2021 | |
| 2021-12-22 | Zimmer Biomet Holdings, Inc. | $88,346 | Royalty or License | Cash or cash equivalent | Trabecular Metal (TM) Ankle Device, Foot & Ankle | 2021 | |
| 2021-12-22 | Merck Sharp & Dohme LLC | $32,945 | Research payment | Cash or cash equivalent | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2021 |
| 2021-12-22 | Alexion Pharmaceuticals, Inc. | $29,743 | Research payment | Cash or cash equivalent | A Randomized Clinical Trial of Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa I | 2021 | |
| 2021-12-22 | Genentech, Inc. | $7,625 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | UNRESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA FOLLOWING DEFINITIVE CONCURRENT CHEMORADIOTHERAPY | 2021 |
| 2021-12-22 | Novo Nordisk AS | $4,470 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2021 |
| 2021-12-22 | PFIZER INC. | $4,122 | Research payment | Cash or cash equivalent | A TWOPART PHASE 1AB OPENLABEL MULTICENTER TRIAL EVALUATING PHARMACOKINETICS SAFETY AND EFFICACY OF PF 07284890 ARRY 461 | 2021 | |
| 2021-12-22 | Gilead Sciences, Inc. | $1,875 | Research payment | Cash or cash equivalent | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn's Disease | 2021 | |
| 2021-12-22 | Kite Pharma, Inc. | $1,587 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Thera | 2021 |
| 2021-12-22 | Gilead Sciences, Inc. | $1,442 | Research payment | Cash or cash equivalent | A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis | 2021 | |
| 2021-12-22 | Intercept Pharmaceuticals, Inc. | $1,309 | Research payment | Cash or cash equivalent | Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic | 2021 | |
| 2021-12-22 | MicroPort Orthopedics Inc | $84 | Research payment | Cash or cash equivalent | MPO Hip System Device, Orthopedic Product | Post Market Surveillance Study of the Wright Medical Technology Metal on Metal Total Hip System | 2021 |
| 2021-12-21 | PFIZER INC. | $101,681 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2021 | |
| 2021-12-21 | PFIZER INC. | $11,982 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2021 |
| 2021-12-21 | Boston Scientific Corporation | $2,419 | Research payment | Cash or cash equivalent | TheraSphere Device, mCRC | Immunotherapy combined with Yttrium-90 RadioEmbolization in the treatment Colorectal Cancer with Liver Metastases [iRE-C | 2021 |
| 2021-12-21 | Chiesi USA, Inc. | $1,769 | Research payment | Cash or cash equivalent | 2021 | ||
| 2021-12-21 | Chiesi USA, Inc. | $1,326 | Research payment | Cash or cash equivalent | 2021 | ||
| 2021-12-21 | Linvatec Corporation | $267 | Long term medical supply or device loan | In-kind items and services | LINVATEC KNEE PRESERVATION SYSTEM Device, ORTHOPEDIC SURGERY | 2021 | |
| 2021-12-20 | F. Hoffmann-La Roche AG | $173,414 | Research payment | Cash or cash equivalent | GENOME-WIDE CRISPRCAS9 SCREEN TO IDENTIFY HOST FACTORS ESSENTIAL FOR THE REPLICATION OF RESPIRATORY VIRUSES | 2021 | |
| 2021-12-20 | Gilead Sciences, Inc. | $23,250 | Research payment | Cash or cash equivalent | Cayston Drug, RESP | Inflection Point in the Course of FEV1/FVC Ratio over Time in Patients with Cystic Fibrosis: Validation of New Outcome M | 2021 |
| 2021-12-20 | GENZYME CORPORATION | $18,270 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2021 | |
| 2021-12-20 | Boston Scientific Corporation | $12,405 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ACURATE IDE | 2021 |
| 2021-12-20 | Janssen Research & Development, LLC | $1,576 | Research payment | Cash or cash equivalent | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2021 | |
| 2021-12-20 | E.R. Squibb & Sons, L.L.C. | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ZEPOSIA Drug, Neuroscience | 2021 | |
| 2021-12-20 | GENZYME CORPORATION | $598 | Research payment | Cash or cash equivalent | MPS-I LSD Data Registry | 2021 | |
| 2021-12-17 | Merck Sharp & Dohme LLC | $187,038 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2021 |
| 2021-12-17 | Merck Sharp & Dohme LLC | $45,762 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv | 2021 |
| 2021-12-17 | Bayer Healthcare Pharmaceuticals Inc. | $6,159 | Research payment | Cash or cash equivalent | Non-Covered | Adaptive dose finding study | 2021 |
| 2021-12-17 | Deciphera Pharmaceuticals Inc. | $5,000 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2021 |
| 2021-12-17 | AstraZeneca Pharmaceuticals LP | $3,983 | Research payment | Cash or cash equivalent | FASENRA Biological, Respiratory | A Phase 4 Multicenter Randomized Double blind Parallel Group Placebo controlled Study to Evaluate the Effect of Benraliz | 2021 |
| 2021-12-17 | Janssen Research & Development, LLC | $3,748 | Research payment | Cash or cash equivalent | A Prospective Multi Center non Interventional Study for the Identification of Biomarker Signatures for the early detecti | 2021 | |
| 2021-12-17 | United Therapeutics Corporation | $3,661 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-12-17 | Deciphera Pharmaceuticals Inc. | $1,500 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2021 |
| 2021-12-17 | Elekta, Inc. | $600 | Consulting Fee | Cash or cash equivalent | ELEKTA UNITY Device, LINAC SOLUTIONS (MR-LINAC) | 2021 | |
| 2021-12-17 | Deciphera Pharmaceuticals Inc. | $109 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2021 |
| 2021-12-17 | Deciphera Pharmaceuticals Inc. | $109 | Research payment | Cash or cash equivalent | QINLOCK Drug, ONCOLOGY | INTRIGUE A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB INTRIGUE | 2021 |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $26,534 | Research payment | Cash or cash equivalent | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBOD | 2021 | |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $16,705 | Research payment | Cash or cash equivalent | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBOD | 2021 | |
| 2021-12-16 | Vanda Pharmaceuticals Inc. | $14,681 | Research payment | Cash or cash equivalent | TOLERABILITY STUDY OF VTR-297 IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES | 2021 | |
| 2021-12-16 | ABBVIE INC. | $2,003 | Research payment | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | A Phase 4 Study to Compare US Marketed Creon Drug Product with Drug Product Manufactured with a Modernized Process at an | 2021 |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $1,637 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS | 2021 |
| 2021-12-16 | Bolton Medical Inc | $1,500 | Research payment | Cash or cash equivalent | RelayPro-IP-0018-12 Device, Device | RelayPro-IP-0018-12 | 2021 |
| 2021-12-16 | Regeneron Pharmaceuticals, Inc. | $1,300 | Research payment | Cash or cash equivalent | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBOD | 2021 | |
| 2021-12-16 | Janssen Research & Development, LLC | $1,225 | Research payment | Cash or cash equivalent | Uptravi Selexipag the users drug registry | 2021 | |
| 2021-12-16 | Alexion Pharmaceuticals, Inc. | $945 | Research payment | Cash or cash equivalent | Long-Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Compl | 2021 | |
| 2021-12-16 | Esperion Therapeutics, Inc. | $218 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-15 | Merck Sharp & Dohme LLC | $64,363 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab versus Placebo as Adjuvant The | 2021 |
| 2021-12-15 | SEAGEN INC. | $10,458 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer | 2021 |
| 2021-12-15 | Clovis Oncology, Inc. | $1,394 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR) | 2021 |
| 2021-12-15 | Medical Device Business Services, Inc. | $565 | Grant | Cash or cash equivalent | 2021 | ||
| 2021-12-14 | PROGENICS PHARMACEUTICALS, INC. | $4,600 | Research payment | Cash or cash equivalent | PYLARIFY Drug, RADIOPHARMACEUTICAL | Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant | 2021 |
| 2021-12-14 | BIOTRONIK INC. | $327 | Research payment | Cash or cash equivalent | Acticor Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2021 |
| 2021-12-14 | BIOTRONIK INC. | $277 | Research payment | Cash or cash equivalent | Acticor Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2021 |
| 2021-12-14 | BIOTRONIK INC. | $180 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2021 |
| 2021-12-14 | BIOTRONIK INC. | $180 | Research payment | Cash or cash equivalent | Plexa Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2021 |
| 2021-12-14 | BIOTRONIK INC. | $180 | Research payment | Cash or cash equivalent | Acticor Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2021 |
| 2021-12-14 | BIOTRONIK INC. | $75 | Research payment | Cash or cash equivalent | Rivacor Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2021 |
| 2021-12-14 | BIOTRONIK INC. | $25 | Research payment | Cash or cash equivalent | Plexa Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2021 |
| 2021-12-14 | BIOTRONIK INC. | $25 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2021 |
| 2021-12-14 | BIOTRONIK INC. | $25 | Research payment | Cash or cash equivalent | Solia Device, Cardiology/Vascular Diseases | BIO-LIBRA | 2021 |
| 2021-12-13 | Alnylam Pharmaceuticals Inc. | $22,894 | Research payment | Cash or cash equivalent | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and | 2021 | |
| 2021-12-13 | Janssen Research & Development, LLC | $7,625 | Research payment | Cash or cash equivalent | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2021 | |
| 2021-12-13 | Roche TCRC, Inc. | $7,449 | Research payment | Cash or cash equivalent | Drug | ORAL TREATMENT OF NPDR | 2021 |
| 2021-12-13 | SANOFI US SERVICES INC. | $4,095 | Research payment | Cash or cash equivalent | KEVZARA Biological, Rheumatology | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With P | 2021 |
| 2021-12-13 | Alnylam Pharmaceuticals Inc. | $4,080 | Research payment | Cash or cash equivalent | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and | 2021 | |
| 2021-12-13 | BIOVERATIV THERAPEUTICS INC. | $3,323 | Research payment | Cash or cash equivalent | A Phase 3 Open-label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagula | 2021 | |
| 2021-12-13 | Alnylam Pharmaceuticals Inc. | $2,282 | Research payment | Cash or cash equivalent | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and | 2021 | |
| 2021-12-13 | Alnylam Pharmaceuticals Inc. | $2,174 | Research payment | Cash or cash equivalent | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and | 2021 | |
| 2021-12-13 | Roche TCRC, Inc. | $1,862 | Research payment | Cash or cash equivalent | Drug | ORAL TREATMENT OF NPDR | 2021 |
| 2021-12-13 | Alnylam Pharmaceuticals Inc. | $1,000 | Research payment | Cash or cash equivalent | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and | 2021 | |
| 2021-12-13 | Alnylam Pharmaceuticals Inc. | $720 | Research payment | Cash or cash equivalent | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and | 2021 | |
| 2021-12-13 | GENZYME CORPORATION | $500 | Space rental or facility fees (teaching hospital only) | In-kind items and services | DUPIXENT Biological, Immunology | 2021 | |
| 2021-12-13 | Alnylam Pharmaceuticals Inc. | $300 | Research payment | Cash or cash equivalent | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and | 2021 | |
| 2021-12-13 | Janssen Research & Development, LLC | $186 | Research payment | Cash or cash equivalent | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2021 | |
| 2021-12-10 | Janssen Research & Development, LLC | $5,240 | Research payment | Cash or cash equivalent | A Randomized Double-blind Placebo controlled Phase 3 Study of the Bruton's Tyrosine Kinase BTK Inhibitor PCI32765 Ibruti | 2021 | |
| 2021-12-10 | Contego Medical, Inc | $4,445 | Research payment | Cash or cash equivalent | Neuroguard IEP Device, Cardiovascular | Performance II | 2021 |
| 2021-12-10 | KYOWA KIRIN, INC. | $350 | Research payment | In-kind items and services | An Open-label, Phase 1 Study of KHK2455 in Combination with Avelumab in Adult Subjects with Locally Advanced or Metastat | 2021 | |
| 2021-12-09 | Bolton Medical Inc | $41,929 | Research payment | Cash or cash equivalent | RelayPro-IP-0018-12 Device, Device | RelayPro-IP-0018-12 | 2021 |
| 2021-12-09 | OSSIO INC | $32,500 | Research payment | Cash or cash equivalent | 2021 | ||
| 2021-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $19,637 | Research payment | Cash or cash equivalent | Emphysema Progression Biomarker Study | 2021 | |
| 2021-12-09 | Spark Therapeutics, Inc. | $3,969 | Research payment | Cash or cash equivalent | LUXTURNA Biological, OCULAR | A POST-AUTHORIZATION, MULTICENTER, LONGITUDINAL, OBSERVATIONAL SAFETY REGISTRY STUDY FOR PATIENTS TREATED WITH VORETIGEN | 2021 |
| 2021-12-09 | ABBVIE INC. | $816 | Research payment | Cash or cash equivalent | A Phase I Study of ABBV-011 as a Single-Agent and in Combination with Budigalimab (ABBV-181) in Subjects with Relapsed o | 2021 | |
| 2021-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $64,718 | Research payment | Cash or cash equivalent | A STUDY OF INTRATHECAL SHP611 IN PARTICIPANTS WITH LATE INFANTILE METACHROMATIC LEUKODYSTROPHY | 2021 | |
| 2021-12-08 | PFIZER INC. | $35,945 | Research payment | Cash or cash equivalent | MAGNETISMM3 AN OPENLABEL MULTICENTER NONRANDOMIZED PHASE 2 STUDY OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS W | 2021 | |
| 2021-12-08 | Edwards Lifesciences Corporation | $12,600 | Research payment | Cash or cash equivalent | CLASP II TR Pivotal, Study No. 2019-07 | 2021 | |
| 2021-12-08 | PFIZER INC. | $9,989 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EF | 2021 | |
| 2021-12-08 | Medical Device Business Services, Inc. | $550 | Research payment | Cash or cash equivalent | ATTUNE Device, Ortho-Knee | Short Medium and Long Term Survivorship of Attune Primary Total Knee Prostheses | 2021 |
| 2021-12-07 | Medtronic, Inc. | $11,778 | Research payment | Cash or cash equivalent | CD HORIZON Device, TL | Investigator Sponsored Research | 2021 |
| 2021-12-07 | PFIZER INC. | $3,250 | Research payment | Cash or cash equivalent | A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PH | 2021 | |
| 2021-12-07 | PFIZER INC. | $1,450 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 1B2 OPENLABEL STUDY TO EVALUATE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB MSB00 | 2021 |
| 2021-12-06 | GENZYME CORPORATION | $18,560 | Research payment | Cash or cash equivalent | A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biw | 2021 | |
| 2021-12-06 | Boston Scientific Corporation | $6,563 | Research payment | Cash or cash equivalent | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | LUX DX PERFORM | 2021 |
| 2021-12-06 | ABBVIE INC. | $6,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | 2021 | |
| 2021-12-06 | Janssen Research & Development, LLC | $4,926 | Research payment | Cash or cash equivalent | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2021 | |
| 2021-12-06 | Boston Scientific Corporation | $3,502 | Research payment | Cash or cash equivalent | General Therapies Device, Therapies | INTERRUPT AF | 2021 |
| 2021-12-06 | PTC Therapeutics, Inc. | $3,023 | Research payment | Cash or cash equivalent | A RANDOMIZED, PARALLEL-ARM, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY WITH OPEN-LABEL EXTENSION TO ASSESS THE EFFICACY AND | 2021 | |
| 2021-12-06 | Boston Scientific Corporation | $279 | Research payment | Cash or cash equivalent | VARIOUS RELEASED ICD FAMILIES Device, Clinical Trial Product | APPRAISE ATP | 2021 |
| 2021-12-04 | PFIZER INC. | $31,085 | Research payment | Cash or cash equivalent | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI | 2021 | |
| 2021-12-04 | PFIZER INC. | $9,177 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-12-04 | PFIZER INC. | $5,360 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT | 2021 |
| 2021-12-03 | Merck Sharp & Dohme LLC | $18,924 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Co | 2021 |
| 2021-12-03 | Merck Sharp & Dohme LLC | $16,500 | Research payment | Cash or cash equivalent | Drug, CARDIOVASCULAR | A Phase 2,3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy a | 2021 |
| 2021-12-03 | Elekta, Inc. | $3,600 | Consulting Fee | Cash or cash equivalent | ELEKTA UNITY Device, LINAC SOLUTIONS (MR-LINAC) | 2021 | |
| 2021-12-03 | Janssen Research & Development, LLC | $1,300 | Research payment | Cash or cash equivalent | A Prospective Multi Center non Interventional Study for the Identification of Biomarker Signatures for the early detecti | 2021 | |
| 2021-12-02 | ABBVIE INC. | $9,316 | Research payment | Cash or cash equivalent | A Phase I Study of ABBV-011 as a Single-Agent and in Combination with Budigalimab (ABBV-181) in Subjects with Relapsed o | 2021 | |
| 2021-12-02 | ABBVIE INC. | $8,000 | Research payment | Cash or cash equivalent | ORILISSA Drug, WOMENS HEALTH | A Phase 3b Study to Evaluate the Safety and Efficacy of Elagolix in Combination with Combined Oral Contraceptives in Pre | 2021 |
| 2021-12-02 | ABBVIE INC. | $5,000 | Research payment | Cash or cash equivalent | MAVYRET Drug, VIROLOGY | A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Ad | 2021 |
| 2021-12-02 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | 2021 | |
| 2021-12-02 | GE HEALTHCARE | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2021 | ||
| 2021-12-01 | PFIZER INC. | $15,753 | Research payment | Cash or cash equivalent | A PHASE 1B 2PART DOUBLEBLIND PLACEBOCONTROLLED SPONSOROPEN STUDY TO EVALUATE THE SAFETY TOLERABILITY AND PHARMACOKINETIC | 2021 | |
| 2021-12-01 | Novo Nordisk AS | $3,927 | Research payment | Cash or cash equivalent | NN8640-4263 | 2021 | |
| 2021-12-01 | Novo Nordisk AS | $1,126 | Research payment | Cash or cash equivalent | NN7769-4513 | 2021 | |
| 2021-12-01 | Esperion Therapeutics, Inc. | $945 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-12-01 | GENZYME CORPORATION | $300 | Space rental or facility fees (teaching hospital only) | In-kind items and services | DUPIXENT Biological, Immunology | 2021 | |
| 2021-12-01 | Boehringer Ingelheim RCV GmbH & Co KG | $50 | Research payment | In-kind items and services | POCC in NASH | 2021 | |
| 2021-11-30 | AstraZeneca Pharmaceuticals LP | $74,399 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | Feasibility and safety of Yttrium Y-90 radioembolization combined with PD-L1 blockade in the treatment of liver-predomin | 2021 |
| 2021-11-30 | AstraZeneca Pharmaceuticals LP | $21,124 | Research payment | Cash or cash equivalent | FASENRA Biological, Respiratory | A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled 3-Part Phase 3 Study to Demonstrate the Eff | 2021 |
| 2021-11-30 | PFIZER INC. | $14,076 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-11-30 | E.R. Squibb & Sons, L.L.C. | $12,874 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate | 2021 | |
| 2021-11-26 | Boston Scientific Corporation | $6,046 | Research payment | Cash or cash equivalent | TheraSphere Device, mCRC | Immunotherapy combined with Yttrium-90 RadioEmbolization in the treatment Colorectal Cancer with Liver Metastases [iRE-C | 2021 |
| 2021-11-25 | PFIZER INC. | $7,609 | Research payment | Cash or cash equivalent | A TWOPART PHASE 1AB OPENLABEL MULTICENTER TRIAL EVALUATING PHARMACOKINETICS SAFETY AND EFFICACY OF PF 07284890 ARRY 461 | 2021 | |
| 2021-11-24 | Novo Nordisk Inc | $85,828 | Research payment | Cash or cash equivalent | Esperoct Biological, Hemophilia | work order for the production of an enzyme at CBB | 2021 |
| 2021-11-24 | PFIZER INC. | $32,729 | Research payment | Cash or cash equivalent | A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EF | 2021 | |
| 2021-11-24 | PFIZER INC. | $24,921 | Research payment | Cash or cash equivalent | MAGNETISMM3 AN OPENLABEL MULTICENTER NONRANDOMIZED PHASE 2 STUDY OF ELRANATAMAB PF06863135 MONOTHERAPY IN PARTICIPANTS W | 2021 | |
| 2021-11-24 | Novo Nordisk AS | $3,932 | Research payment | Cash or cash equivalent | Wegovy Drug, Obesity | EX9536-4388 | 2021 |
| 2021-11-24 | Novo Nordisk AS | $3,123 | Research payment | Cash or cash equivalent | Esperoct Biological, Hemophilia | NN7088-3908 | 2021 |
| 2021-11-24 | United Therapeutics Corporation | $659 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | ADAPT - A PATIENT REGISTRY OF THE REAL-WORLD USE OF ORENITRAM | 2021 |
| 2021-11-24 | La Jolla Pharmaceutical Company | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | GIAPREZA Drug, EMERGENT HYPOTENSION | 2021 | |
| 2021-11-23 | PFIZER INC. | $186,277 | Research payment | Cash or cash equivalent | COMIRNATY Biological, VACCINES | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2021 |
| 2021-11-23 | Eli Lilly and Company | $26,459 | Research payment | Cash or cash equivalent | THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU | 2021 | |
| 2021-11-23 | United Therapeutics Corporation | $2,277 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RALINEPAG WHEN ADDE | 2021 | |
| 2021-11-23 | SEAGEN INC. | $1,000 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trast | 2021 |
| 2021-11-23 | Esperion Therapeutics, Inc. | $622 | Research payment | Cash or cash equivalent | NEXLETOL Drug, ANTILIPEMIC AGENTS | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENC | 2021 |
| 2021-11-23 | Boehringer Ingelheim France S.A.S. | $484 | Research payment | In-kind items and services | TRADJENTA Drug, DIABETES | 52 wks Eff. & Saf. Ph III in Paediatrics | 2021 |
| 2021-11-23 | PFIZER INC. | $318 | Research payment | Cash or cash equivalent | A RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG | 2021 |
The latest 200 records of 2,240.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Iowa City, IA, county Johnson County, IA, state Iowa; placed by its city name.
| Measure | Place (city or town) Iowa City, IA | County Johnson County, IA | State Iowa |
|---|---|---|---|
| Population B01003 | 75,752 | 156,639 | 3,210,507 |
| Population, 2020 census P1 | 74,828 | 152,854 | 3,190,369 |
| Median age B01002 | 26.2 | 31.0 | 38.6 |
| Under 18 B01001 | 14.3% | 19.3% | 22.9% |
| 65 and over B01001 | 12.3% | 13.3% | 18.1% |
| Households B11001 | 30,816 | 63,341 | 1,315,707 |
| Foreign born B05002 | 12.2% | 9.8% | 5.9% |
| Median household income B19013 | $58,546 | $74,935 | $75,059 |
| Median family income B19113 | $111,960 | $118,607 | $97,491 |
| Per capita income B19301 | $37,842 | $45,136 | $40,877 |
| Poverty rate B17001 | 26.3% | 17.1% | 11.1% |
| Unemployment rate B23025 | 4.6% | 3.8% | 3.6% |
| Civilian labor force B23025 | 45,244 | 90,024 | 1,699,994 |
| Mean commute (minutes) B08013 | 17.3 | 19.4 | 19.8 |
| Bachelor's degree or higher B15003 | 60.5% | 55.2% | 31.4% |
| Housing units B25001 | 33,863 | 68,217 | 1,437,699 |
| Owner-occupied B25003 | 47.2% | 59.4% | 71.7% |
| Renters B25003 | 52.8% | 40.6% | 28.3% |
| Median home value B25077 | $285,900 | $308,600 | $208,000 |
| Median gross rent B25064 | $1,094 | $1,122 | $972 |
| White, not Hispanic B03002 | 70.4% | 74.8% | 82.3% |
| Black B03002 | 9.4% | 7.6% | 3.8% |
| Hispanic or Latino B03002 | 8.1% | 6.7% | 7.3% |
| Asian B03002 | 7.1% | 5.6% | 2.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.2% |
Economy now FRED unemployment 3.2% in Sep 2026 (3.4% a year earlier); per capita personal income $67,321 in 2025, up 28% in five years (+2.8% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Iowa City, IA.
Comments